Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
about
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaAcute promyelocytic leukemia: where did we start, where are we now, and the futureA review of arsenic trioxide and acute promyelocytic leukemiaEnhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell lineExpression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsThe role of gemtuzumab ozogamicin in acute leukaemia therapy.Advances in the treatment for haematological malignancies.Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinGemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Gemtuzumab ozogamicin in acute myeloid leukemia.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia.Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.Applications of monoclonal antibodies for the treatment of hematological malignancies
P2860
Q26783425-AD3A0A19-FB57-4246-90A2-D870E6C97621Q26830385-E3E4DA0B-70EA-4924-96E6-E97597C21C98Q28087768-B31C788D-5F1F-41B8-A0A1-319984446023Q28238144-367DC481-187D-4840-AD20-81CD3343B38DQ35051695-743202BE-D8C8-485F-A52C-B5CD71BDDE86Q36367816-99CDA969-20D5-4030-9B46-4AC4E55A4DD0Q36429723-D1F5AA50-2EED-498E-9582-8911EE6A31BCQ36938551-188AC42F-0380-4913-9D41-BB8751F845BBQ37818248-18385052-63AA-434C-82D8-85DD7F264C1DQ38055497-5343C45B-2C7B-4CC7-B528-55773CB211EEQ38109541-B5494C12-7556-4AA6-BE9E-21978969663AQ38355000-1E79A0C0-976C-47C4-A327-148B17C0C9BEQ38728718-04FE2592-D271-49FB-B9D8-2F27B32702FAQ40413191-4814411C-110C-426F-8C02-5D6C79096304Q42720957-32BF42E3-2F1D-441E-9EE9-22A857501567Q43195338-2C9CB62D-CC16-4714-9005-1F119E54C21BQ44073282-9253609A-A118-4CA8-AF3F-7C697600D263Q57904664-D2CC001B-56AB-4343-A0E6-4F659F2E981B
P2860
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Efficacy of gemtuzumab ozogami ...... elocytic leukemia (APL) cells.
@en
Efficacy of gemtuzumab ozogami ...... t acute promyelocytic leukemia
@nl
type
label
Efficacy of gemtuzumab ozogami ...... elocytic leukemia (APL) cells.
@en
Efficacy of gemtuzumab ozogami ...... t acute promyelocytic leukemia
@nl
prefLabel
Efficacy of gemtuzumab ozogami ...... elocytic leukemia (APL) cells.
@en
Efficacy of gemtuzumab ozogami ...... t acute promyelocytic leukemia
@nl
P2093
P2860
P356
P1433
P1476
Efficacy of gemtuzumab ozogami ...... elocytic leukemia (APL) cells.
@en
P2093
A Takeshita
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403807
P577
2005-08-01T00:00:00Z
P5875
P6179
1034357311